Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Painkyl** is a brand name for fentanyl buccal soluble film, a mucoadhesive formulation designed for rapid transmucosal delivery of fentanyl, an opioid agonist, to manage breakthrough cancer pain in opioid-tolerant adult patients already on around-the-clock opioid therapy. It consists of two layers—a mucoadhesive layer containing fentanyl and an inactive layer to limit oral diffusion—with approximately 50% of the dose absorbed rapidly via the buccal mucosa for high bioavailability and quick onset. Developed using BioDelivery Sciences' BEMA technology and marketed by partners like TTY Biopharm in certain regions, it provides significant pain intensity reduction versus placebo in trials, though typical opioid adverse events such as nausea and vomiting occur.[1][8][9]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Painkyl.